Under construction – not a live service
Sign in
Taking people in SingaporeNo phase

Records Asian patients with advanced EGFR exon 20 insertion lung cancer

Collects information on how this lung cancer affects Asian adults over 21 years.

Plain-language title generated from the registry record
Registry title: A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Key facts

Where
Singapore, SingaporeSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 99 years old?

Source: NCT06418412, who can take part

Where in Singapore

  • National Cancer Centre SingaporeSingapore, SingaporeTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
National Cancer Centre, Singapore
Trial code
NCT06418412
Record updated
12 June 2025
Original description
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.Read full original descriptionShow less

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)

There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.

This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.

Inclusion: Histologically confirmed advanced NSCLC; Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation; Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data); Male or female adults, age as defined by local regulations.

Exclusion: Patients without an EGFR exon 20 insertion mutation.

ClinicalTrials.gov NCT06418412